Armored human TREM2 CAR T cells are engineered to target TREM2-positive tumor-associated macrophages (TAMs) rather than tumor antigens. These cells locally secrete IL-12 through a tumor microenvironment–responsive biosensor, deplete TAMs, reprogram the tumor microenvironment, and promote tumor regression with no systemic toxicity reported.
The approach aims to overcome TAM-mediated immunosuppression and broaden applicability to solid tumors. Uncertainty: outcomes beyond the reported preclinical context and comprehensive toxicity data are not specified in the provided content.
Cancer Cell published a clinical update in Oncology on 22 Jan 2026.
The item focuses on Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells.
Review the original article for the full source wording and details.